erlotinib has been researched along with bekanamycin in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (bekanamycin) | Trials (bekanamycin) | Recent Studies (post-2010) (bekanamycin) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 118 | 4 | 39 |
| Protein | Taxonomy | erlotinib (IC50) | bekanamycin (IC50) |
|---|---|---|---|
| 3-oxoacyl-[acyl-carrier-protein] synthase 3 | Escherichia coli | 6.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Makawana, JA; Sun, J; Zhu, HL | 1 |
| Lin, L; Makawana, JA; Sangani, CB; Teraiya, SB; Zhang, X; Zhu, HL | 1 |
2 other study(ies) available for erlotinib and bekanamycin
| Article | Year |
|---|---|
Schiff's base derivatives bearing nitroimidazole moiety: new class of antibacterial, anticancer agents and potential EGFR tyrosine kinase inhibitors.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Microbial Sensitivity Tests; Models, Molecular; Nitroimidazoles; Protein Kinase Inhibitors; Schiff Bases; Structure-Activity Relationship; Thermodynamics | 2013 |
Design, synthesis and molecular modeling of pyrazole-quinoline-pyridine hybrids as a new class of antimicrobial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Docking Simulation; Pyrazoles; Pyridines; Quinolines; Structure-Activity Relationship | 2014 |